These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 18979533)

  • 1. Investigation of the effect of heating on the chemistry and antifactor Xa activity of enoxaparin.
    Patel RP; Narkowicz C; Jacobson GA
    J Pharm Sci; 2009 May; 98(5):1700-11. PubMed ID: 18979533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of freezing- and thawing-induced biological, chemical, and physical changes to enoxaparin solution.
    Patel RP; Narkowicz C; Jacobson GA
    J Pharm Sci; 2009 Mar; 98(3):1118-28. PubMed ID: 18661541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Xa stability of diluted enoxaparin for use in pediatrics.
    Dager WE; Gosselin RC; King JH; Christensen CL; Owings JT; Larkin EC
    Ann Pharmacother; 2004 Apr; 38(4):569-73. PubMed ID: 14982984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties.
    Shastri MD; Johns C; Hutchinson JP; Khandagale M; Patel RP
    Anal Bioanal Chem; 2013 Jul; 405(18):6043-52. PubMed ID: 23712644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro stability of enoxaparin solutions (20 mg/mL) diluted in 4% glucose.
    Patel RP; Narkowicz C; Jacobson GA
    Clin Ther; 2008 Oct; 30(10):1880-5. PubMed ID: 19014843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin III-Binding Site Analysis of Low-Molecular-Weight Heparin Fractions.
    Chen Y; Zhao J; Yu Y; Liu X; Lin L; Zhang F; Linhardt RJ
    J Pharm Sci; 2018 May; 107(5):1290-1295. PubMed ID: 29339133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the interaction of dextran and enoxaparin on haemostasis in humans.
    Matthiasson SE; Lindblad B; Mätzsch T; Molin J; Qvarford P; Bergqvist D
    Thromb Haemost; 1994 Nov; 72(5):722-7. PubMed ID: 7534945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of plasma anti-Xa activities with different lots of enoxaparin.
    Gosselin RC; King JH; Janatpour KA; Dager WE; Larkin EC; Owings JT
    Ann Pharmacother; 2004 Apr; 38(4):563-8. PubMed ID: 14982983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of persistent anti-Xa activity following administration of the low molecular weight heparin enoxaparin sodium (Clexane).
    Brieger D; Dawes J
    Thromb Haemost; 1994 Aug; 72(2):275-80. PubMed ID: 7831665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H; Faraklas I; Saffle J; Cochran A
    J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of structural characteristics and anticoagulation activity of enoxaparin sodium with different degree of 1,6-anhydro derivatives].
    Zhu H; Liü YJ; Han XW; Liu SL; Hao JJ; Zhao XL; Yu GL
    Yao Xue Xue Bao; 2014 Jul; 49(7):1049-53. PubMed ID: 25233639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analytical comparison of a US generic enoxaparin with the originator product: The focus on comparative assessment of antithrombin-binding components.
    Mourier PAJ; Herman F; Sizun P; Viskov C
    J Pharm Biomed Anal; 2016 Sep; 129():542-550. PubMed ID: 27497655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism.
    Yogaratnam D; Smith BS; Angood PB; Gandhi PJ
    Pharmacotherapy; 2004 Dec; 24(12):1793-9. PubMed ID: 15585445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels.
    Peters BJ; Hofer M; Daniels CE; Winters JL
    Am J Health Syst Pharm; 2018 Dec; 75(23):1883-1888. PubMed ID: 30463865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stability and sterility of diluted enoxaparin under three different storage conditions.
    Summerhayes R; Chan M; Ignjatovic V; Prankerd R; Monagle P
    J Paediatr Child Health; 2011 May; 47(5):299-301. PubMed ID: 21244553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations.
    Dalmora SL; Júnior LB; Schmidt CA; Vaccari SF; Oliveira PR; Codevilla CF
    J AOAC Int; 2004; 87(6):1305-8. PubMed ID: 15675440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin.
    Guerrini M; Elli S; Gaudesi D; Torri G; Casu B; Mourier P; Herman F; Boudier C; Lorenz M; Viskov C
    J Med Chem; 2010 Nov; 53(22):8030-40. PubMed ID: 21028827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of an anti-activated factor X (anti-Xa) assay for the quantification of enoxaparin in human plasma.
    Al-Sallami HS; Medlicott NJ
    J Pharm Pharmacol; 2015 Feb; 67(2):209-14. PubMed ID: 25557692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.